Vitiligo Clinical Trials

Find Vitiligo Clinical Trials Near You

A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo

Status: Recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• The participant has a diagnosis of active or stable vitiligo for at least 3 months.

• The participant has a body mass index (BMI) within the range of 18.5 to 40.0 kg/m2

• A female participant is eligible if she is not pregnant or breastfeeding AND is a woman of nonchildbearing potential OR is a women of childbearing potential using a contraceptive method that is highly effective AND agrees not to donate eggs for the purpose of reproduction for the required period

• A male participant is eligible if he agrees to refrain from donating sperm PLUS remain abstinent from heterosexual intercourse OR use a male condom with a female partner for the required period

• The participant is capable of giving signed, informed consent

• The participant agrees to discontinue all agents and procedures used to treat vitiligo during the treatment period in the trial

• If receiving permitted concomitant medications for any reason other than vitiligo, the participant must be on a stable regimen,

• The participant must agree to avoid prolonged exposure to the sun, must use sunscreen, and must not use tanning booths, sun lamps, or other ultraviolet light sources

⁃ NOTE - Additional criteria apply, please contact the investigator for more information

Locations
United States
Arkansas
Teva Investigational Site 12052
RECRUITING
Hot Springs
Arizona
Teva Investigational Site 12043
TERMINATED
Scottsdale
California
Teva Investigational Site 12044
RECRUITING
Fremont
Teva Investigational Site 12051
ACTIVE_NOT_RECRUITING
Irvine
Teva Investigational Site 12046
ACTIVE_NOT_RECRUITING
Pasadena
Florida
Teva Investigational Site 12049
ACTIVE_NOT_RECRUITING
Miramar
Illinois
Teva Investigational Site 12047
ACTIVE_NOT_RECRUITING
Chicago
Kentucky
Teva Investigational Site 12053
ACTIVE_NOT_RECRUITING
Louisville
Michigan
Teva Investigational Site 12048
ACTIVE_NOT_RECRUITING
Canton
Oregon
Teva Investigational Site 12054
RECRUITING
Portland
Texas
Teva Investigational Site 12045
ACTIVE_NOT_RECRUITING
Dallas
Teva Investigational Site 12057
ACTIVE_NOT_RECRUITING
Webster
Utah
Teva Investigational Site 12055
ACTIVE_NOT_RECRUITING
South Jordan
Contact Information
Primary
Teva U.S. Medical Information
USMedInfo@tevapharm.com
1-888-483-8279
Time Frame
Start Date: 2024-11-11
Estimated Completion Date: 2029-01-31
Participants
Target number of participants: 66
Treatments
Experimental: Cohort 1
Dose A
Experimental: Cohort 2
Dose A
Experimental: Cohort 3
Dose B
Related Therapeutic Areas
Sponsors
Leads: Teva Branded Pharmaceutical Products R&D LLC

This content was sourced from clinicaltrials.gov

Similar Clinical Trials